Evidence map›Paper›PMID 32995671›Full record

ArticleBioactive materials2021

Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer.

Ye Liang, Yonghua Wang, Liping Wang, Zhijuan Liang, Dan Li, Xiaoyu Xu, Yuanbin Chen, Xuecheng Yang, Hongbo Zhang, Haitao Niu

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Bioactive materials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 179 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Hyaluronic Acid-Functionalized Highly Porous Polymeric Materials for Stem Cell Culture.Chemistry of materials : a publication of the American Chemical Society · 2025
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Nanomedicine in Bladder Cancer Therapy.International journal of molecular sciences · 2024
    Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Ye LiangKey Laboratory of Urology and Andrology, Medical Research Centre, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Yonghua WangKey Laboratory of Urology and Andrology, Medical Research Centre, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Liping WangKey Laboratory of Urology and Andrology, Medical Research Centre, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Zhijuan LiangKey Laboratory of Urology and Andrology, Medical Research Centre, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Dan LiKey Laboratory of Urology and Andrology, Medical Research Centre, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Xiaoyu XuPharmaceutical Sciences Laboratory and Turku Bioscience Centre, Åbo Akademi University, Turku, 20520, Finland.
Yuanbin ChenKey Laboratory of Urology and Andrology, Medical Research Centre, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Xuecheng YangDepartment of Urology, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Hongbo ZhangPharmaceutical Sciences Laboratory and Turku Bioscience Centre, Åbo Akademi University, Turku, 20520, Finland.
Haitao NiuKey Laboratory of Urology and Andrology, Medical Research Centre, Affiliated Hospital of Qingdao University, Qingdao, 266003, China.
Qingdao University · CNÅbo Akademi University · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer is one of the concerning malignancies worldwide, which is lacking effective targeted therapy. Gene therapy is a potential approach for bladder cancer treatment. While, a safe and effective targeted gene delivery system is urgently needed for prompting the bladder cancer treatment

Indexed as

Bladder cancerCD44 targetingChitosanHyaluronic acid dialdehydesiRNA delivery

Identifiers

PMID32995671
PMCPMC7490593
OpenAlexW3083957683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.